FirstHealth of the Carolinas

Clinical Trial Details

Study Title: SWOG 1117: A Randomized Phase II Study of Azacitidine in Combination With Lenalidomide vs. Azacitidine Alone vs. Azacititdine in Combination With Vorinostat for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Study Type: Interventional
Study Condition: Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Investigator: Dr. Charles Kuzma
Phone: (910) 715-3500
Research Coordinator: Lori DeSpain
Phone: (910) 715-2200
Eligibility Criteria: Women and men ages 18 and older, diagnosed with myelodysplastic syndrome or chronic myelomonocytic leukemia. For additional criteria, call the Research Coordinator or visit the study weblink.
Sponsor Organization: Southwest Oncology Group
Study Rationale: Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or stopping them from dividing. Lenalidomide may stop the growth of cancer cells by stopping blood flow to the cancer. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether azacitidine is more effective with or without lenalidomide or vorinostat in treating myelodysplastic syndromes or chronic myelomonocytic leukemia.
Study Purpose: This randomized phase II trial studies how well giving azacitidine works with or without lenalidomide or vorinostat in treating patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.
Study Link: http://clinicaltrials.gov/show/NCT01522976
   
 
FirstHealth @ Facebook.comFirstHealth @ Twitter.comFirstHealth @ Pinterest.comFirstHealth @ LinkedIn.com
Physicians Employees
Working Together, First in Quality, First in Health
Site MapPrivacy PolicyTerms & ConditionsHelp © FirstHealth of the Carolinas, Inc.